pioglitazone has been researched along with Sclerosis, Systemic in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonelli, A | 1 |
| Ferri, C | 1 |
| Ferrari, SM | 1 |
| Colaci, M | 1 |
| Ruffilli, I | 1 |
| Sebastiani, M | 1 |
| Fallahi, P | 1 |
1 other study available for pioglitazone and Sclerosis, Systemic
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts.
Topics: Adult; Aged; Apoptosis; Cell Proliferation; Cell Survival; Cells, Cultured; Female; Fibroblasts; Hum | 2013 |